Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous induction therapy in patients with moderately to severely active ulcerative colitis.

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

This is especially crucial for those undergoing colectomy or starting biologic treatments like vedolizumab (an immunosuppressive therapy for both Crohn's disease and ulcerative colitis ...

Entyvio (vedolizumab, Takeda Pharmaceuticals). The researchers enrolled 2,286 ustekinumab-treated patients with ulcerative colitis, who were propensity-score matched 1:1 with vedolizumab-treated ...

Opens in a new tab or window SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness of vedolizumab (Entyvio) versus ustekinumab ...

Over a 3-year period, MACE occurred in 10.3% of patients taking ustekinumab and 12.2% of patients taking vedolizumab for those with ulcerative colitis (adjusted HR 0.88, 95% CI 0.74-1.05), and in ...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase I clinical trial ...

gmx.com Objective While infliximab combined to thiopurines is more effective than infliximab monotherapy in patients with Crohn’s disease (CD) and UC, the impact of adding thiopurines to vedolizumab ...

Our research The gastrointestinal (GI) epidemiology group focus on research on GI organs and diseases. Most of that research is based on the ESPRESSO study, which you can read more about on a separate ...